Logo

Enzene Receives Marketing Authorization for Teriparatide (biosimilar) in India

Share this

Enzene Receives Marketing Authorization for Teriparatide (biosimilar) in India

Shots:

  • The company received DCGI’s MA for Teriparatide (biosimilar) for the treatment of Osteoporosis vs anti-resorptive therapies such as bisphosphates and SERMs
  • The approved product will be marketed through Alkem Laboratories as well as it explore other potential partnering opportunities
  • Teriparatide will be launched in a fully compliant pen device

 ­ Ref: PRNewswire | Image: PRNewswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions